Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. (2016)

First Author: D'Avola D
Attributed to:  Overcoming immunological barriers to regenerative medicine funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.jhep.2016.05.012

PubMed Identifier: 27212246

Publication URI: http://europepmc.org/abstract/MED/27212246

Type: Journal Article/Review

Volume: 65

Parent Publication: Journal of hepatology

Issue: 4

ISSN: 0168-8278